3 UK Stocks Estimated To Be Trading Below Intrinsic Value By At Least 12.8%

The UK stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China, highlighting concerns about global economic recovery. In such an environment, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential long-term gains.

Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom

Name	Current Price	Fair Value (Est)	Discount (Est)
Playtech (LSE:PTEC)	£3.92	£7.45	47.4%
On the Beach Group (LSE:OTB)	£1.894	£3.72	49%
Next 15 Group (AIM:NFG)	£3.185	£6.32	49.6%
Invinity Energy Systems (AIM:IES)	£0.239	£0.46	47.6%
Fevara (LSE:FVA)	£1.45	£2.89	49.8%
Eurocell (LSE:ECEL)	£1.18	£2.24	47.4%
Entain (LSE:ENT)	£5.376	£10.07	46.6%
Convatec Group (LSE:CTEC)	£2.26	£4.22	46.5%
AstraZeneca (LSE:AZN)	£122.40	£229.07	46.6%
Advanced Medical Solutions Group (AIM:AMS)	£2.815	£5.12	45%

Click here to see the full list of 47 stocks from our Undervalued UK Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

AstraZeneca (LSE:AZN)

Overview: AstraZeneca PLC is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines with a market capitalization of approximately £189.85 billion.

Operations: The company's revenue is primarily derived from its pharmaceuticals segment, which generated $61.37 billion.

Estimated Discount To Fair Value: 46.6%

AstraZeneca appears undervalued based on cash flow analysis, with its current trading price of £122.4 significantly below the estimated future cash flow value of £229.07. Despite high debt levels, AstraZeneca's earnings are expected to grow at 13.8% annually, outpacing the UK market average and indicating potential for value appreciation. Recent developments in oncology treatments and strategic alliances further strengthen its position in the pharmaceutical sector, potentially enhancing future revenue streams despite slower-than-market revenue growth forecasts.

• Upon reviewing our latest growth report, AstraZeneca's projected financial performance appears quite optimistic.
• Take a closer look at AstraZeneca's balance sheet health here in our report.

BAE Systems (LSE:BA.)

Overview: BAE Systems plc is a global company offering defense, aerospace, and security solutions across regions including the United States, the United Kingdom, the Middle East, Australia, Saudi Arabia, and Europe with a market cap of £60.20 billion.

Operations: The company's revenue segments are comprised of Air (£7.73 billion), Maritime (£6.72 billion), Electronic Systems (£7.79 billion), Cyber & Intelligence (£2.41 billion), and Platforms & Services (£5.27 billion).

Estimated Discount To Fair Value: 14.2%

BAE Systems is trading at £21.26, below its estimated future cash flow value of £24.78, suggesting it may be undervalued based on cash flows. Earnings are forecast to grow 11.8% annually, faster than the UK market average, with a strong return on equity projection of 20.2%. Recent advancements in defense technology and strategic contracts bolster its growth prospects despite moderate revenue growth forecasts and limited undervaluation margin compared to future cash flow estimates.

• Our growth report here indicates BAE Systems may be poised for an improving outlook.
• Delve into the full analysis health report here for a deeper understanding of BAE Systems.

Babcock International Group (LSE:BAB)

Overview: Babcock International Group PLC is involved in the design, development, manufacture, and integration of specialist systems for aerospace, defense, and security across various regions including the UK and internationally, with a market cap of £5.41 billion.

Operations: The company's revenue segments consist of £1.08 billion from Land, £1.59 billion from Marine, £2.07 billion from Nuclear, and £431.40 million from Aviation.

Estimated Discount To Fair Value: 12.8%

Babcock International Group, trading at £11.05, is undervalued relative to its estimated future cash flow value of £12.67, with a 12.8% discount below fair value. Earnings are projected to grow 18.8% annually, outpacing the UK market's average growth rate and indicating strong potential for profit expansion despite slower revenue growth forecasts of 5.1%. Recent management changes and a completed fixed income offering of £248.72 million could impact strategic direction and financial flexibility moving forward.

• Our expertly prepared growth report on Babcock International Group implies its future financial outlook may be stronger than recent results.
• Click here to discover the nuances of Babcock International Group with our detailed financial health report.

Key Takeaways

• Explore the 47 names from our Undervalued UK Stocks Based On Cash Flows screener here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com